A two-part, open-label, randomized, phase 2/3 study of dinutuximab and irinotecan versus irinotecan for second-line treatment of subjects with relapsed or refractory small cell lung cancer.
2018 ◽
Vol 36
(15_suppl)
◽
pp. TPS8588-TPS8588
◽
Keyword(s):
Phase 2
◽
2016 ◽
Vol 17
(8)
◽
pp. 1147-1157
◽
Keyword(s):
2020 ◽
Vol 21
(9)
◽
pp. 1224-1233
◽
Keyword(s):